Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332384 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 573
- Enrollment target
NCT00332384 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 573 participants.
The verdict
NCT00332384, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 573 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
Interventions
- DRUG brimonidine/timolol fixed combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 2000-01 |
| Est. Completion | 2001-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332384
The ClinicalTrials.gov registry entry for NCT00332384 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 573 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which brimonidine/timolol fixed combination is the first listed.
NCT00332384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00332384 about?
NCT00332384 is a clinical study titled "Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension". The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
What is the current status of trial NCT00332384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 573 participants. The study started on 2000-01. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00332384?
The interventions under investigation include: brimonidine/timolol fixed combination (DRUG).
Who is sponsoring clinical trial NCT00332384?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.